Search research articles
Contact Us
Filters
Showing results (1-10 of 83) with videos related to
Page
of 9
Sort By:
Nature Metabolism
|
March 21, 2025
GLP-2 attenuates antipsychotics' adverse metabolic effects
Sandra Pereira, Margaret K Hahn
Schizophrenia Bulletin
|
May 12, 2020
Mortality Risk Following Acute Coronary Syndrome Among Patients With Schizophrenia Spectrum Disorders-Addressing the Gaps
Margaret K Hahn, Roshni Panda
The Journal of Endocrinology
|
January 10, 2024
In vivo techniques for assessment of insulin sensitivity and glucose metabolism
Margaret K Hahn, Adria Giacca, Sandra Pereira
The Annals of Pharmacotherapy
|
July 1, 2010
Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain
Margaret K Hahn, Tony Cohn, Gary Remington
Clinical Schizophrenia & Related Psychoses
|
January 11, 2013
Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters
Margaret K Hahn, Tony Cohn, Celine Teo, et al.
Journal of Clinical Psychopharmacology
|
November 25, 2010
Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects
Margaret K Hahn, Gary Remington, Daniel Bois, et al.
Psychoneuroendocrinology
|
February 26, 2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons
Chantel Kowalchuk, Pruntha Kanagasundaram, Denise D Belsham, et al.
Neuroscience and Biobehavioral Reviews
|
October 25, 2016
Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies
Davide Amato, Clare L Beasley, Margaret K Hahn, et al.
Frontiers in Psychiatry
|
October 15, 2021
Editorial: Cardiovascular and Physical Health in Severe Mental Illness
Sri Mahavir Agarwal, Anthony Christopher Vernon, Ganesan Venkatasubramanian, et al.
Journal of Clinical Psychopharmacology
|
November 17, 2022
Addressing Metabolic Comorbidity in Individuals With Intellectual and Developmental Disability on Antipsychotics: A Clinical Case Series
Nicolette Stogios, Margaret K Hahn, Yona Lunsky, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 83) with videos related to
Sort By:
Page
of 9
Nature Metabolism
|
March 21, 2025
GLP-2 attenuates antipsychotics' adverse metabolic effects
Sandra Pereira, Margaret K Hahn
Schizophrenia Bulletin
|
May 12, 2020
Mortality Risk Following Acute Coronary Syndrome Among Patients With Schizophrenia Spectrum Disorders-Addressing the Gaps
Margaret K Hahn, Roshni Panda
The Journal of Endocrinology
|
January 10, 2024
In vivo techniques for assessment of insulin sensitivity and glucose metabolism
Margaret K Hahn, Adria Giacca, Sandra Pereira
The Annals of Pharmacotherapy
|
July 1, 2010
Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain
Margaret K Hahn, Tony Cohn, Gary Remington
Clinical Schizophrenia & Related Psychoses
|
January 11, 2013
Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters
Margaret K Hahn, Tony Cohn, Celine Teo, et al.
Journal of Clinical Psychopharmacology
|
November 25, 2010
Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects
Margaret K Hahn, Gary Remington, Daniel Bois, et al.
Psychoneuroendocrinology
|
February 26, 2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons
Chantel Kowalchuk, Pruntha Kanagasundaram, Denise D Belsham, et al.
Neuroscience and Biobehavioral Reviews
|
October 25, 2016
Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies
Davide Amato, Clare L Beasley, Margaret K Hahn, et al.
Frontiers in Psychiatry
|
October 15, 2021
Editorial: Cardiovascular and Physical Health in Severe Mental Illness
Sri Mahavir Agarwal, Anthony Christopher Vernon, Ganesan Venkatasubramanian, et al.
Journal of Clinical Psychopharmacology
|
November 17, 2022
Addressing Metabolic Comorbidity in Individuals With Intellectual and Developmental Disability on Antipsychotics: A Clinical Case Series
Nicolette Stogios, Margaret K Hahn, Yona Lunsky, et al.
Page
of 9